Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Qilu Pharmaceutical Co., Ltd.
BeOne Medicines
Bayer
Psyence Australia Pty Ltd
Convalife (Shanghai) Co., Ltd.
University of California, Irvine
Neonc Technologies, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Jazz Pharmaceuticals
Blue Earth Diagnostics
Qurient Co., Ltd.
Seagen Inc.
AstraZeneca
Arvinas Inc.
Tizona Therapeutics, Inc
Essen Biotech
Genentech, Inc.
National Institutes of Health Clinical Center (CC)
BioNTech SE
NiKang Therapeutics, Inc.
Poseida Therapeutics, Inc.
MacroGenics
AstraZeneca
DualityBio Inc.
Daiichi Sankyo
Beijing Tide Pharmaceutical Co., Ltd
SN BioScience
Cue Biopharma
Perspective Therapeutics
MOMA Therapeutics
Second Life Therapeutics
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Innate Pharma
M.D. Anderson Cancer Center
GlaxoSmithKline
University of Pittsburgh
Tanabe Pharma America, Inc.
Blueprint Medicines Corporation
HiFiBiO Therapeutics
Hospices Civils de Lyon
BicycleTx Limited
National Institutes of Health Clinical Center (CC)
SystImmune Inc.
Rondo Therapeutics
GE Healthcare
Actym Therapeutics, Inc.